Investors at BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
50 investors are at BIO-Europe 2026 — 52 presentations on the program. Most represented: Sofinnova Partners (3 on the program), Andera Partners (2 on the program), Earlybird Venture Capital (2 on the program). 10 of them have their own page in this guide. As of Sep 29, 2026.
Track
Top represented
Showing 1–17 of 50 organizations
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Sofinnova Partners Paris, France | |
Life sciences venture capital firm investing from seed to late stage in biotech, medtech and industrial biotech. | Panel Mon Nov 9 17:00–17:45 AI in the Lab: Why Greater Efficiency Could Mean More Drugs, Not Fewer Scientists Why AI that forms hypotheses and guides experiments could mean more drug candidates, not fewer scientists, and how to pick which to pursue. Ecosystem InnovationBusiness of Biotech Panel Mon Nov 9 16:00–16:45 Cell and Gene Therapy: What Should You Know? Where cell and gene therapies stand today, what recent clinical and sales data show, and how funding and partnerships are changing. Panel Mon Nov 9 16:00–16:45 Fuelling Innovation: The State of Early-Stage Investment in Biotech Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting. |
Andera Partners Paris, France | |
Private equity firm whose life sciences team invests in biotech and medtech companies through its BioDiscovery funds. | Keynote Mon Nov 9 12:00–12:45 Building a competitive and impactful European biotech community: Perspectives from the European Life Sciences Coalition and CEOs How Europe can keep biotech talent, money and companies at home by drawing in big investors, speeding regulation and building stronger stock markets. Ecosystem InnovationBusiness of Biotech Panel Mon Nov 9 14:00–14:45 Voices from the IPO Class of ’25/’26: What’s Next? Leaders of biotechs that listed on the stock market in 2025 and 2026 describe life after going public and the hurdles they face. |
Earlybird Venture Capital Berlin, Germany | |
European venture capital firm investing in technology and health companies. | Panel Mon Nov 9 16:00–16:45 Fuelling Innovation: The State of Early-Stage Investment in Biotech Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting. Panel Wed Nov 11 13:00–13:45 AI-Powered Ecosystems: Transforming Drug Discovery Through Digital Collaboration How drug, biotech and tech companies can build AI partnerships, and why AI finds easier wins in early discovery than in later clinical stages. |
European Investment Bank Luxembourg, Luxembourg | |
The European Union's lending institution, providing loans and venture debt, including to life sciences companies. | Panel Tue Nov 10 14:30–14:55 Investing in Women’s Health: How Can Europe Scale Innovation? How Europe can grow investment in women's health, previewing a European Investment Bank study of the field's research, unmet needs and funding options. Panel Tue Nov 10 11:15–12:15 Women’s Health: Healthcare’s Largest Underserved Market and Biggest Growth Opportunity Why women's health is a large, neglected market, and how much value is lost when medicine is designed around the wrong default patient. Therapeutic InsightsBusiness of Biotech |
Novo Holdings Hellerup, Denmark | |
Life-science investment company that manages the Novo Nordisk Foundation's assets, investing in companies from early-stage biotech to mature healthcare businesses. | Panel Mon Nov 9 16:15–17:00 Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work? What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies. Panel Wed Nov 11 09:00–09:45 Beyond the inhaler: The respiratory market New drugs and targets for asthma, chronic obstructive lung disease and pulmonary fibrosis, and where investors and partners are now putting money. |
AP Asabys Partners Barcelona, Spain | |
Venture capital firm investing in healthcare and life sciences companies. | Panel Tue Nov 10 15:00–15:45 Longevity – Are we getting younger? What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape. |
High-Tech Gründerfonds Bonn, Germany | |
German seed-stage venture capital investor in technology start-ups, including life sciences. | Panel Mon Nov 9 16:00–16:45 Fuelling Innovation: The State of Early-Stage Investment in Biotech Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting. |
Jeito Capital Paris, France | |
Paris-based private equity investor financing biotech and medical innovation companies. | Panel Tue Nov 10 15:00–15:45 Scaling Success: The Dynamics of Late-Stage Investment in Biotech How investors back biotechs whose products are close to market, from regulatory hurdles and scaling up to going public or being acquired. |
Seroba Dublin, Ireland | |
European venture capital firm investing in biotech and medtech companies, mainly at seed and Series A. | Panel Mon Nov 9 14:00–14:45 ADCs in oncology: What does the data show? What the latest data show on how well and how safely antibody–drug conjugates treat cancer, and which technologies and targets attract investors. |
Venture capital firm investing in clinical-stage biotherapeutics companies in Europe and the US. | Panel Mon Nov 9 16:15–17:00 Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work? What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies. |
AV Angelini Ventures Rome, Italy | |
Corporate venture capital arm of Angelini Industries, investing in biotech, medtech and digital health companies. | Keynote Mon Nov 9 12:00–12:45 Building a competitive and impactful European biotech community: Perspectives from the European Life Sciences Coalition and CEOs How Europe can keep biotech talent, money and companies at home by drawing in big investors, speeding regulation and building stronger stock markets. Ecosystem InnovationBusiness of Biotech Panel Tue Nov 10 17:00–17:45 Resilient by Design: Reinventing Biopharma Alliances in a Fragmenting World How drug companies are reshaping research and manufacturing partnerships to stay reliable as political tensions and supply chain risks divide the world. Business of BiotechBiomanufacturing Strategy |
LifeArc London, United Kingdom | |
UK medical research charity that funds translational research and invests in early-stage life sciences companies through LifeArc Ventures. | Panel Tue Nov 10 16:00–16:45 At the Board Table: Navigating Power Dynamics and Building Senior Stakeholder Trust (In collaboration with YVC) How younger executives and junior investors on biotech boards can earn senior members' trust and help drive decisions. Panel Tue Nov 10 10:00–10:45 Cardiometabolic innovations beyond GLP-1 – Where are we now? Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going. |
ESC Advisors New York, NY | ◇Silver Sponsor |
Boutique healthcare investment bank advising life sciences companies on capital raising, business development and strategy. | Keynote Tue Nov 10 13:00–13:45 Keynote: Day in the Life of an experienced dealmaker Experienced drug-company dealmakers and venture investors share how they see the life sciences industry today and how biotechs can find their way. |
◇Silver Sponsor | |
Life sciences investment bank advising on licensing, mergers and acquisitions, and capital raising. | Keynote Tue Nov 10 13:00–13:45 Keynote: Day in the Life of an experienced dealmaker Experienced drug-company dealmakers and venture investors share how they see the life sciences industry today and how biotechs can find their way. |
◇Silver Sponsor | |
Life science venture firm investing in early-stage therapeutics and commercial-stage medtech, diagnostics and late-stage therapeutics. | Panel Tue Nov 10 15:00–15:45 Scaling Success: The Dynamics of Late-Stage Investment in Biotech How investors back biotechs whose products are close to market, from regulatory hurdles and scaling up to going public or being acquired. |
A Abingworth London, United Kingdom | |
Life sciences investment firm that invests in therapeutics companies and funds late-stage clinical development. | Panel Mon Nov 9 13:00–14:00 Navigating partnering and business development in a shifting global landscape How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples. |
A ATHOS Munich, Germany | |
Munich family office making long-term investments in biotechnology and healthcare companies. | Panel Tue Nov 10 14:30–14:55 The Next Generation of European Entrepreneurs: From Scientific Innovation to Life Sciences Impact What makes a successful life sciences founder, and how founders in Europe can turn discoveries into biotech companies that compete worldwide. |
Instantly find 20 buyers from investors
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse BIO-Europe 2026 by
Organization type
Track
Everyone
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction